Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices

See what CB Insights has to offer

Founded Year

2012

Stage

Debt - III | Alive

Total Raised

$36.77M

Last Raised

$120K | 2 yrs ago

About NeuroTronik

NeuroTronik develops neurostimulation therapy for the enhancement of heart function in the hospital or clinic. Its medical technology helps physicians treat heart failure patients who come to the hospital because of their worsened symptoms. NeuroTronik CANS Therapy is cardiac autonomic nerve stimulation delivered via a NeuroCatheter, placed temporarily in a vein just above the heart, in combination with a NeuroModulator, positioned bedside.

NeuroTronik Headquarter Location

4021 Stirrup Creek Drive Suite 210

Durham, North Carolina, 27703,

United States

919-883-3220

Latest NeuroTronik News

Nearly 1 in 4 hospitalized patients with HF, COVID-19 die

Jan 15, 2021

Disclosures: Solomon reports he received grants from Alnylam, Amgen, AstraZeneca, Bellrophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, Neurotronik, NIH/NHLBI, Novartis, Respicardia, Sanofi and Theracos. Please see the study for all other authors’ relevant financial disclosures. The editorial authors report no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Patients with HF and COVID-19 had high risk for complications, with nearly 1 in 4 dying during hospitalization, researchers reported. Name “Patients with heart failure have lower reserve, in general, than people without severe cardiovascular disease, and they are at increased risk from many respiratory infections, including influenza,” Scott D. Solomon, MD, professor of medicine at Harvard Medical School and senior physician at Brigham and Women’s Hospital, told Healio. “In addition, patients with cardiovascular disease, in general, appear to be at greater risk for COVID-19-related complications.” Source: Adobe Stock Researchers assessed the Premier Healthcare Database to identify patients with at least one HF hospitalization or two related outpatient visits from 2019 to March 2020 who were then hospitalized from April to September 2020. Predictors of in-hospital mortality were identified among patients with HF hospitalized with COVID-19 . The researchers also compared this population and those hospitalized due to other factors. There were 132,312 patients with a history of HF hospitalized from April to September 2020, with 23,843 hospitalized with acute HF, 8,383 hospitalized with COVID-19 and 100,068 hospitalized for alternative causes. In-hospital mortality COVID-19 hospitalization was associated with higher odds of in-hospital mortality compared with acute HF hospitalization (24.2% vs. 2.6%). Researchers observed strongest associations during April 2020 (adjusted OR = 14.48; 95% CI, 12.25-17.12) compared with other months (aOR = 10.11; 95% CI, 8.95-11.42; P for interaction < .001). Male sex (aOR = 1.26; 95% CI, 1.13-1.4) and morbid obesity (aOR = 1.25; 95% CI, 1.07-1.46) were associated with higher odds of in-hospital mortality among patients with HF hospitalized with COVID-19. Age (aOR per 10 years = 1.35; 95% CI, 1.29-1.42) and admission early in the pandemic (aOR range from May to September vs. April, 0.35 to 0.64) were also associated with in-hospital mortality among this population. “The best way to avoid COVID-related adverse outcomes is to avoid contracting COVID. For heart failure patients, this means that they need to wear masks religiously and be especially careful about physical distancing, even with family members who don’t live in their household,” Solomon said. “Heart failure patients should be high on the list to receive vaccines as they become available.” Disproportionate burden According to an accompanying editorial, patients with HF hospitalized with COVID-19 were more likely to be Black and/or Hispanic, which was consistent with previous evidence of the disproportionate COVID-19 burden on traditionally underrepresented groups. Ersilia M. DeFilippis “The reasons for these glaring disparities are complex and include high housing density, lower socioeconomic status and, most importantly, poor access to health care due to structural inequities in society,” Ersilia M. DeFilippis, MD, cardiology fellow at Columbia University Irving Medical Center, and colleagues wrote. “Such patients are also highly represented in the food services business and other classes of essential workers, further increasing their risk for infection with COVID-19.” To mitigate the risk to patients with HF during COVID-19, DeFilippis and colleagues suggested focusing efforts on strategies to minimize inequalities such as making testing easily accessible, facilitating contact tracing in highly dense communities and providing spaces to allow social isolation for families living in overcrowded housing. “These results should remind us to be innovative and thoughtful in our management of patients with HF while trying to maintain equity and good health for all,” DeFilippis and colleagues wrote. Reference:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NeuroTronik

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeuroTronik is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,889 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

NeuroTronik Patents

NeuroTronik has filed 17 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Neurotechnology
  • Neurophysiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/20/2019

12/21/2021

Cardiac arrhythmia, Cardiovascular physiology, Implants (medicine), Cardiac anatomy, Cardiology

Grant

Application Date

2/20/2019

Grant Date

12/21/2021

Title

Related Topics

Cardiac arrhythmia, Cardiovascular physiology, Implants (medicine), Cardiac anatomy, Cardiology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.